THE REGISTER AS A MEANS OF IMPROVING THE QUALITY OF MUCOVISCIDOSIS PATIENTS’ TREATMENT
https://doi.org/10.15690/pf.v9i3.330
Abstract
The creation of a register of mucoviscidosis (MV) patients is necessary for determining the epidemic situation in the region, evaluating the efficacy of therapeutic strategies and the quality of healthcare provided. The regional register of Yaroslavl contains information about 53 MV patients. The average age of these patients is 12.9 years, the amount of patients older than 18 is 22.7%, the average age of diagnosis is 3.4 years. The overall survival median is 26.8 years (by the beginning of 2012). The prevalence of the disease is 1:8005 newborns according to the results of neonatal screening. The amount of patients infected with Pseudomonas aeruginosa and Burkholderia cepacia is 30,2% and 2,5% respectively. The F508del mutation occurs in 43,4% of all cases. The next most prevalent mutations are N1303K, 394delTT, CFTRdele2,3 (21kb) (4,72% each), the number of unidentified mutations is only 8.49%. A comparative evaluation of therapeutic approaches (basic therapy) was conducted in the Yaroslavl region and in a number of European countries. Data obtained from the register allows to solve not only clinical and epidemiological problems, but also sort out organizational issues, plan medicine provisions and conduct medical and social rehabilitation.
About the Authors
I. K. Asherova
City Child Hospital of Yaroslavl № 1
Russian Federation
Russian Federation
N. I. Kapranov
Medical and Genetic Centre, RAMS, Moscow
Russian Federation
Russian Federation
References
1. CF Foundation Patient Registry 2007. ECFS Patient Registry Report 2007 data.
2. D ring G., Hoiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibr. 2004; 3: 67–91.
3. Krasovsky S., Cherniak A., Amelina E. et al. Survival analysis of cystic fibrosis (CF) patients in the Moscow region of Russia in 2000–2010. Abstr. 372. J Cyst. Fibr. 2011; 10 (1): S95.
4. Cystic Fibrosis in children and adults. The leeds method of management (nov. 7). St James University Hospital, UK. 2008.
5. Гинтер Е. К., Капранов Н. И., Петрова Н. В. и др. Муковисцидоз. В кн.: Генетика бронхолегочных заболеваний. М.: Атмосфера. 2010. С. 51–78.
6. Капустина Т. Ю. Изменения печени и их коррекция при муковисцидозе у детей. Автореф. дис. канд. мед. наук. М. 2001.
7. Каширская Н. Ю. Состояние желудочно-кишечного тракта, поджелудочной железы и гепатобилиарной системы у больных муковисцидозом. Автореф. дис. докт. мед. наук. М. 2001.
8. Dondos V., Westaby D. Liver, biliary and pancreatic disease. Cystic Fibrosis, third edition. Ed. by M. Hodson, D. Geddes, A. Bush. London. 2007. Р. 225–235.
9. Saiman L., Anstead M., Mayer-Hamblett N. et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trail. JAMA. 2010; 303: 1707–1715.
10. Капранов Н. И., Каширская Н. Ю., Шерман В. Д. и др. Муковис цидоз: Современные достижения и актуальные проблемы. Мето дические рекомендации. Москва. 2011. С. 64–65.
11. Frederiksen B., Pressler T., Hansen A., Koch C. Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonisation in patients with cystic fibrosis. Acta Paediatr. 2006; 95: 1070–1074.
12. Paul K., Rietschel E., Ballman M. et al. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Bronchoalveolar lavage for the evaluation of anti-inflammatory treatment study group. Am J Respir Crit Care Med. 2004; 169: 719–725.
13. Шелепнева Н. Е., Каширская Н. Ю., Шерман В. Д. и др. Клиническое значение дорназы альфа (Пульмозим) в комплексной терапии детей раннего возраста, страдающих муковисцидозом. Фарматека. 2009; 6: 1–4.
14. Shah P. L., Conway S. P., Scott S. F. et al. A case-controlled study with dornase alfa to evaluate impact on disease progression over a 4-year period. Respiration. 2001; 68: 160–164.
15. Hodson M. E., McKenzie S., Harms H. K. et al. Dornase alfa in the treatment of cystic fibrosis in Europe: A report from the epidemiologic registry of cystic fibrosis. Pediatr Pulmonol. 2003; 36: 427–432.
16. George Р. М., Banya W., Pareek N. et al. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. BMJ. 2011; 342: d1008. Doi: 10.1136/bmj.d1008.
Review
For citations:
Asherova I.K., Kapranov N.I. THE REGISTER AS A MEANS OF IMPROVING THE QUALITY OF MUCOVISCIDOSIS PATIENTS’ TREATMENT. Pediatric pharmacology. 2012;9(3):96-101. (In Russ.) https://doi.org/10.15690/pf.v9i3.330
Views:
747
Email this article 